

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

HDQ-P1

RRID:CVCL_2067

Type: Cell Line

Proper Citation

RRID:CVCL_2067

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2067

Proper Citation: RRID:CVCL_2067

Description: Cell line HDQ-P1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:10913678](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24176112](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:34339474](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HDQ-P1

Synonyms: HDQP1

Cross References: CLO:CLO_0009911, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03471695, BioSample:SAMN10988509, cancercellines:CVCL_2067, Cell_Model_Passport:SIDM01062, ChEMBL-Cells:ChEMBL4482998, ChEMBL-Targets:ChEMBL4483244, Cosmic:1995439, Cosmic:2164995, Cosmic-CLP:1290922, DepMap:ACH-000643, DSMZ:ACC-494, DSMZCellDive:ACC-494, EGA:EGAS00001000978, GDSC:1290922, GEO:GSM827279, GEO:GSM887066, GEO:GSM888136, GEO:GSM1172970, GEO:GSM1669872,

IARC_TP53:17911, LiGeA:CCLE_297, LINCS_LDP:LCL-1481, Lonza:1216, Pharmacodb:HDQP1_522_2019, PRIDE:PXD030304, Progenetix:CVCL_2067, PubChem_Cell_line:CVCL_2067, Wikidata:Q54882190

ID: CVCL_2067

Record Creation Time: 20220427T220323+0000

Record Last Update: 20260913T004001+0000

Ratings and Alerts

No rating or validation information has been found for HDQ-P1.

No alerts have been found for HDQ-P1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.